Article
Outlooks for Pfizer, Arena and Onyx Following Busy May
Healthcare investor Nate Sadeghi says Pfizer's arthritis drug and Arena's obesity drug will be approved, while confidence in Onyx's cancer drug has increased.
07:02AM 05/21/12
Article
A Health Care Fortnight for the Record Books
Health care investor Nate Sadeghi says Pfizer is holding back bad news on its Alzheimer's drug, tells Human Genome to sell to Glaxo and likes Vertex and Gilead Sciences.
07:00AM 05/14/12
Article
Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix
A closer look at Bristol-Myers Squibb's hepatitis C drug BMS-094 raises troubling questions.
07:00AM 05/07/12
Article
Grading Hep C Stocks Exiting EASL Confab
Healthcare investor Nathan Sadeghi-Nejad grades the hepatitis C drug stocks following the closely watched EASL conference.
09:44AM 04/23/12
Article
Calling Shenanigans on Amylin Pharma
Too many question, not enough answers regarding Bristol-Myers Squibb's supposed interest in buying Amylin.
07:00AM 04/16/12
Article
Gilead And The Future of HIV Therapy
Gilead's market dominance in HIV is not in peril but the company faces legitimate questions about its ability to innovate.
08:09AM 04/09/12
Article
Regeneron, Amgen And The 'Hope Creation Cycle"
Cholesterol-lowering PCSK9 Inhibitors are real drugs but won't meet aggressive sales forecasts
07:00AM 04/02/12
Article
On Nowruz, Reviewing Drug Stock Picks
TheStreet's biotech contributor Nathan Sadeghi-Nejad looks back at his hits and misses with Amylin, Elan, Gilead Sciences, Onyx and Verastem.
07:00AM 03/26/12
Article
Onyx Pharma: An Underdog Worth Buying
The unexpected approval of a new multiple myeloma drug could be a big upside surprise for Onyx Pharma shares.
06:59AM 03/19/12
Article
Verastem and the Broken Wall Street Research Model
Verastem is a buy only because sell-side analysts are afraid to anger their investment banking overlords.
07:00AM 03/12/12
Connect with TheStreet